WO2014018671A1 - Therapeutic compounds for the treatment of cancer - Google Patents
Therapeutic compounds for the treatment of cancer Download PDFInfo
- Publication number
- WO2014018671A1 WO2014018671A1 PCT/US2013/051885 US2013051885W WO2014018671A1 WO 2014018671 A1 WO2014018671 A1 WO 2014018671A1 US 2013051885 W US2013051885 W US 2013051885W WO 2014018671 A1 WO2014018671 A1 WO 2014018671A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- colomitide
- formula
- pharmaceutically acceptable
- salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 115
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 17
- 201000011510 cancer Diseases 0.000 title claims abstract description 13
- 230000001225 therapeutic effect Effects 0.000 title claims description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 36
- 230000037361 pathway Effects 0.000 claims abstract description 14
- -1 (Q-C^alkoxycarbonyl Chemical group 0.000 claims description 36
- 241001465754 Metazoa Species 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 125000004423 acyloxy group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 125000005862 (C1-C6)alkanoyl group Chemical group 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 238000013160 medical therapy Methods 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 229930195556 colomitide Natural products 0.000 description 68
- 210000004027 cell Anatomy 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 230000008929 regeneration Effects 0.000 description 15
- 238000011069 regeneration method Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 210000002919 epithelial cell Anatomy 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 14
- 239000007788 liquid Substances 0.000 description 11
- 238000005100 correlation spectroscopy Methods 0.000 description 10
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 241000252212 Danio rerio Species 0.000 description 9
- 108091008794 FGF receptors Proteins 0.000 description 9
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 9
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 7
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 7
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 6
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- LYIHRLYQELBUKR-UHFFFAOYSA-N colomitide B Natural products CCC(C)C(=O)C1COC2(C)OCC1C2C LYIHRLYQELBUKR-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000000270 postfertilization Effects 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000002266 amputation Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CDEURGJCGCHYFH-DJLDLDEBSA-N 5-ethynyl-2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C#C)=C1 CDEURGJCGCHYFH-DJLDLDEBSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000002038 ethyl acetate fraction Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000007730 Akt signaling Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 0 C[C@@]([C@@]1CO2)[C@]2(C)OC[C@@]1C(*)(*)* Chemical compound C[C@@]([C@@]1CO2)[C@]2(C)OC[C@@]1C(*)(*)* 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 238000012288 TUNEL assay Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000012750 in vivo screening Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000001418 larval effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000000276 neural tube Anatomy 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229940072040 tricaine Drugs 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- CDEURGJCGCHYFH-UHFFFAOYSA-N 5-ethynyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1C(O)C(CO)OC1N1C(=O)NC(=O)C(C#C)=C1 CDEURGJCGCHYFH-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- DDLZLOKCJHBUHD-WAVHTBQISA-N 6-bromoindirubin-3'-oxime Chemical compound O=C/1NC2=CC(Br)=CC=C2C\1=C\1/C(=N/O)/C2=CC=CC=C2N/1 DDLZLOKCJHBUHD-WAVHTBQISA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- ZVWMFVORWMTJLS-NAWOPXAZSA-N CC[C@@H](C)C[C@@H]1[C@@H](CO2)[C@@H](C)[C@]2(C)OC1 Chemical compound CC[C@@H](C)C[C@@H]1[C@@H](CO2)[C@@H](C)[C@]2(C)OC1 ZVWMFVORWMTJLS-NAWOPXAZSA-N 0.000 description 1
- 241001534149 Cadophora Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108090000424 NADPH Oxidase 1 Proteins 0.000 description 1
- 102100021873 NADPH oxidase 1 Human genes 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- PKOMXLRKGNITKG-UHFFFAOYSA-L calcium;hydroxy(methyl)arsinate Chemical compound [Ca+2].C[As](O)([O-])=O.C[As](O)([O-])=O PKOMXLRKGNITKG-UHFFFAOYSA-L 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- SAQUSDSPQYQNBG-UHFFFAOYSA-N chembl355496 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC(Br)=CC=C21 SAQUSDSPQYQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 150000003881 polyketide derivatives Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000001896 rotating frame Overhauser effect spectroscopy Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- KPZSTOVTJYRDIO-UHFFFAOYSA-K trichlorocerium;heptahydrate Chemical compound O.O.O.O.O.O.O.Cl[Ce](Cl)Cl KPZSTOVTJYRDIO-UHFFFAOYSA-K 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- RTK receptor tyrosine kinase
- FGFR Fibroblast Growth Factor Receptor
- RTK small molecule receptor tyrosine kinase
- Natural products represent a validated source of structurally diverse and biologically active compounds that have been historically successful as anti-cancer agents and cellular tools: for example, rapamycin, an immunosuppressant obtained from Streptomyces hygroscopicus is also a potent anticancer agent which acts by specifically inhibiting mammalian target of rapamycin (mTOR) kinase.
- mTOR mammalian target of rapamycin
- tumorsphere Treatment of two-week old tumorspheres with colomitide C resulted in the reversal of the transformation process and return to the smaller, hollow "normal" mammosphere state within one day. Staining studies with labeled cellular markers showed that colomitide C treatment leads to upregulation of apoptosis in FGFR activated cells. Pharmacokinetic studies demonstrated that colomitide C is stable in both blood plasma and liver microscomes.
- R 1 is (C]-C 6 )alkyl, (C 2 -C 6 )alkenyl, or (C C 6 )alkynyl, wherein each (C 1 -C 6 )alkyl, (C 2 - C 6 )alkenyl, and (Q-C ⁇ alkynyl is optionally substituted with one or more groups independently selected from halo, (Ci-C ⁇ alkoxy, (C 1 -C 6 )alkoxycarbonyl, and (C 1 -C 6 )alkanoyloxy;
- R a is H or (d-C ⁇ alkanoyl
- R b and R c are each independently selected from H, and (C 1 -C 6 )alkanoyl;
- R d is hydroxy, (C ! -C )alkoxy, -NR b R c , or (C 1 -C 6 )alkanoyloxy, wherein the (C 1 -C 6 )alkoxy and (C!-C 6 )alkanoyloxy are each optionally substituted with one or more groups independently selected from halo, (Q-C ⁇ alkoxy, (C 1 -C 6 )alkoxycarbonyl, aryl, and (C 1 -C 6 )alkanoyloxy, and wherein each aryl is optionally substituted with one or more groups independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifiuoromethoxy, (C 1 -C 6 )alkoxy, (Q-C ⁇ alkoxycarbonyl, and (Ci- C 6 )alkanoyloxy;
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
- the invention also provides a method for treating or preventing cancer in an animal comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to the animal.
- the invention also provides a method for modulating the FGF1R pathway in a cell comprising contacting the cell with a compound of formula I or a salt thereof.
- the invention also provides a method for treating a pathological condition associated with the FGF1R pathway in an animal comprising administering a compound of formula I or a
- the invention also provides a compound of formula I or a pharmaceutically acceptable salt thereof for use in medical therapy.
- the invention also provides a compound of formula I or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of cancer.
- the invention also provides a compound of formula I or a pharmaceutically acceptable salt thereof for prophylactic or therapeutic treatment of a condition associated with the FGF1R pathway.
- the invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof to prepare a medicament for treating cancer in an animal (e.g. a mammal such as a human).
- an animal e.g. a mammal such as a human.
- the invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof to prepare a medicament for treating a pathological condition associated with the FGF1R pathway in an animal (e.g. a mammal such as a human).
- an animal e.g. a mammal such as a human.
- the invention also provides a whole animal in vivo screen for FGF signaling modulators using a larval zebrafish tail regeneration system as described herein.
- the invention also provides processes and intermediates disclosed herein that are useful for preparing a compound of formula I or a salt thereof.
- Figure 1 Larvae fin amputation and regeneration
- A Normal larvae fin at 4 days post fertilization.
- B Amputation is performed at the bold vertical line red line.
- C Normal larvae fin at 6 days post fertilization.
- D Regenerated larvae fin at 6 days post fertilization, 2 days after amputation.
- Vertical dotted line indicates the amputated level.
- the shape of the fin is outlined by a curved dotted line.
- FIG. 2 Images of regenerating fins after treating with DMSO (A, Control) and BIO (B). Dotted and solid vertical lines represent the amputation plane and the distal edge of the regenerating fin, respectively. Horizontal arrows represent the length to be measured.
- Figure 3 Colomitide C can reverse the proliferative phenotype in iFGFRl mammary epithelial cells.
- Figure 4 shows that Colomitide C can inhibit proliferation and induce apoptosis in iFGFRl mammary epithelial cells.
- the top panel shows the total number of iFGFRl cells seen by using a using a dye (Hoechst33342) that has been untreated or treated with Colomitide C. While all four untreated iFGFRl cells can take up EdU, which suggests that they are proliferating, only 2 out of 20 iFGFRl cells treated with Colomitide C are shown to take up EdU, suggesting that majority of these cells are not proliferating following the treatment of Colomitide C (middle panel). Also, most of the Colomitide C treated iFGFRl cells are shown to undergo apoptosis as shown by TUNEL assay, while none of the control untreated cells are undergoing apoptosis.
- FIG. 5 Colomitide C inhibits phosphorylation of AKT and affects the downstream targets of AKT signaling pathway.
- Colomitide C can inhibit proliferation and induce apoptosis in human breast cancer cell lines.
- Three breast cancer cell lines, MDA-MB-361, CAMA1 and HCC38 were treated with or without Colomitide C and tested for proliferation (EdU incorporation) and apoptosis (TUNEL).
- EdU incorporation proliferation
- TUNEL apoptosis
- FIG. 7 Colomitide C targets phosphorylation of AKT in HCC38 human breast cancer cells.
- a known inhibitor SU5402 is used as a control.
- halo is fluoro, chloro, bromo, or iodo.
- Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as propyl embraces only the straight chain radical, a branched chain isomer such as isopropyl being specifically referred to.
- Aryl denotes a phenyl radical or an ortho- fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic.
- (Ci-C ⁇ alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl;
- (C 1 -C6)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso- butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy;
- (C 2 -C 6 )alkenyl can be vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1- hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl; (C 2 -C 6 )alkyn
- the compound of formula I is a compound of formula (la):
- the compound of formula I is a compound of formula (lb):
- the compound of formula I is a compound of formula (Id):
- the compound of formula I is a compound of formula (Ie):
- R 1 is (C 1 -C 6 )alkyl.
- R 1 is 1-methylpropyl.
- R 2 is H and R 3 is -OH or NH 2 .
- R d is hydroxy
- R d is (C 1 -C 6 )alkoxy optionally substituted with one or more groups independently selected from halo, (CrC 6 )alkoxy, (CrC ⁇ alkoxycarbonyl, aryl, and (Ci- C 6 )alkanoyloxy, wherein each aryl is optionally substituted with one or more groups independently selected from halo.
- R d is (C 1 -C 6 )alkanoyloxy, optionally substituted with one or more groups independently selected from halo,
- R d is benzyloxy, phenylcarbonyloxy, amino, or a-trifluoromethyl-a- methoxybenzyl.
- the compound of formula I is not colomitide C.
- the invention provides colomotide C in isolated or purified form (e.g. at least about 80, 90, 95, or 99% pure).
- the compound of formula I is not colomitide A. In another embodiment the compound of formula I is not colomitide B. In one embodiment the compound of formula I is not colomitide A or colomitide B. In one embodiment the compound of formula I is not colomitide A, colomitide B or colomitide C.
- An intermediate useful for preparing a compound of formula I is a compound of the following formula
- Another intermediate useful for preparing a compound of formula I is a compound of the following formula
- An intermediate useful for preparing a compound of formula 1(b), is a compound of the following formula
- An intermediate useful for preparing a compound of formula 1(c), 1(d) or 1(e), is a compound of the following formula
- Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate, and a- glycerophosphate.
- Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
- salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion.
- a sufficiently basic compound such as an amine
- a suitable acid affording a physiologically acceptable anion.
- Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
- the compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
- the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
- a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier.
- the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Such compositions and preparations should contain at least 0.1% of active compound.
- the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form.
- the amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
- the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
- a liquid carrier such as a vegetable oil or a polyethylene glycol.
- any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
- the active compound may be incorporated into sustained-release preparations and devices.
- the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
- Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
- the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
- the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
- the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
- the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as
- compositions or formulations in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
- Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like.
- Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
- Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use.
- the resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
- Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
- Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
- the amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
- the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
- the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
- the biological activity of a compound of the invention may be determined using pharmacological models which are well known to the art, or using Test A described below.
- Regeneration of the tail fin of zebrafish larvae was used as one of biological assays.
- the assay was a modification of a procedure reported by Kawakami A, et al., Dev Dyn. 2004, 231(4): 693-699.
- Zebrafish housing, mating, embryo collection, and raising larvae are performed by following standard procedures in the Zebrafish Book (Westerfield, M. (2000). The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio). 4th ed., Univ. of Oregon Press, Eugene). Zebrafish larvae used in the assay were not given any food during the assay period (up to 6 days post fertilization). Embryos and larvae were developed at 28°C in the embryo media. For anesthetizing, approximately 1% volume of tricaine (MS-222) solution (40 mg/ml) was added to larvae.
- MS-222 tricaine
- a larva was placed on a transparent plastic dish, and associated liquid was removed by absorbing it using Kimwipe, so that the larva attached to the dish.
- the tail was cut with a razor blade at the immediately caudal level of the neural tube (Fig. 1). The cutting was made perpendicular to the neural tube.
- magnification of the Zeiss V8 Discovery stereomicroscope was x8.
- the longest length of regenerated area was determined by i Solution software by measuring the pixel number of the line that was drawn perpendicular to the amputation plane (Fig. 2).
- the average of regenerated lengths of the control group was set as 1.00, and regenerated length of each larva was calculated.
- the regenerated length by treating larvae with a compound was evaluated in comparison to a control group, and statistical significance was determined by Student's t-test. If the p value was smaller than 0.05, it was considered that the compound has significant activity of either enhancing or inhibiting regeneration. If more than three larvae of a control group (treated by DMSO) were dead, it was considered that the quality of the larvae of the specific batch was bad, and the entire data of the assay was not used to evaluate any compound in the assay.
- BIO has been shown to impair larvae fin regeneration in a similar, but not identical assay (Lijoy K. Mathew, et al., FASEB J. 2008 August; 22(8): 3087-3096). Thus, if larvae treated by BIO did not show statistically significant inhibition of fin regeneration, it was considered that the quality of the larvae of the specific batch was bad, and the entire data of the assay was not used to evaluate any compound in the assay. If more than three larvae of a treated group were dead, the compound in the assay was not evaluated.
- the biological activity of a compound of the invention may also be determined using pharmacological models which are well known to the art, or using Test B described below.
- Colomitide C was tested for the fin regeneration assay. As shown in Table 1, at 10 ug/ml, colomitide C inhibited fin regeneration. The degree of regenerated lengths was 74.8 ⁇ 1.9%, compared to DMSO treated control larvae.
- BIO (0.5 nM) 40 51.6 41 47 0 44.90 5.43 0.656 0.846 0.672 0.771 0.736 0.089 0.004
- Benzyl-colomitide C was tested in the larvae fin regeneration assay. As shown in Table 2, it showed toxicity at 10 ug/ml. However, as shown in Table 3, at lower concentrations, it exhibited an inhibitory activity on fin regeneration.
- Colomitide C can have any effect on specific signaling pathways which are found to be upregulated in cancer.
- a mouse model system where the FGFRl signaling pathway can be induced via a FGFRl dimerizer, AP20187 was used.
- Upregulation of FGFRl in the mammary epithelial cells results into uncontrolled proliferation of these cells which can be assayed by transformed acinar structure in the matrigel ( Figure 3 A).
- Colomitide C can prevent the transformation of these cells upon FGFRl activation. Additionally, it can reverse the phenotype when applied to the FGFRl mediated transformed acinar structures.
- Colomitide C can inhibit transformation of iFGFRl mammary epithelial cells, proliferation and apoptosis assays of these cells in presence and absence of Colomitide C was carried out. As shown in Figure 4, Colomitide C can inhibit the iFGFRl mammary epithelial cells to incorporate 5-ethynyl-2'-deoxyuridine (EdU), which suggest that Colomitide C inhibits proliferation of these cells. More strikingly, TUNEL assay shows that iFGFRl mammary epithelial cells undergo apoptosis in presence of Colomitide C when FGFR1 is upregulated ( Figure 4).
- EdU 5-ethynyl-2'-deoxyuridine
- Colomitide C affects AKT phosphorylation in iFGFRl mammary epithelial cells
- GFR1 can mediate activation of several sinaling pathways, including induction of ERK1/2 and AKT signaling pathways. These are marked by phosphorylation of the ERK1/2 and/or AKT. Aberrant phosphorylation of these two proteins are found in many cancers. Western analysis of these two proteins was carried out. Whereas phosphorylation of ERKl/2 remains unaffected,
- Colomitide C can inhibit proliferation and induce apoptosis in human breast cancer cells
- Colomitide C can have therapeutic potential in human cancers.
- MDA-MB 361, CAMA 1, and HCC 38 All these cell lines are known to have aberrant FGFR signaling.
- All the three breast cancer cell lines have dramatic reduction in proliferation and induction of apoptosis, as seen previously in the iFGFRl mammary epithelial cells ( Figure 6).
- the AKT phosphorylation was reduced in the Colomitide C treated HCC38 cells, suggesting that for this breast cancer cell line, Colomitide C is likely affecting the AKT signaling pathway (Figure 7).
- the above experiments provide strong proof of principle that
- Colomitide C can have anti-cancer activity and can be of therapeutic value.
- the strain was cultured in 20 erlenmeyer flask containing 100 g rice media at room temperature. After 30 days, the culture was extracted with two times 4 liters of methanol and two times 4 liters of ethylacetate, consecutively. The extracts were combined and dried in the vacuum. Dried extract was suspensed in 500 ml of water and then partitioned with 500 ml of ethylacetete. Dried ethylacetate extract was then dissolved in 500 ml of 90 % methanol (v/v in water) and extracted with 250 ml of n-hexane. Methanol extracts (later called as ethylacetate extracts) was dried and further processed for the isolation of colomitide C (1)
- fraction 24.53 The next fractions (called fraction 24.53 ; 3324.5 mg)was re-separated using 50 g silica with linear gradient elution of 100 % to 0 % of n-hexane/ethylacetate to obtain more colomitide C (1) (970.2 mg).
- Total colomitide C (1) isolated from this culture was 2773 mg.
- Colomitide C (1) (28 mg ; 0.12 mmol) and cerium chloride heptahydrate (92 mg ; 0.32 mmol) were dissolved in 1 ml methanol. While stirring at 0°C, sodium borohydride (9.3 mg ; 0.24 mmol) was added into solution and the reaction was continued at 0°C for 1 hr. After the mixture was kept at -20° C for 24 hr, it was then dried out and portioned between water and EtOAC. Ethylacetate fraction (25.6 mg) was then subjected to a separation using preparative HPLC with gradient elution 35% - 100 % of acetonitrile/H 2 0. Three isomers of products 2 (70 %), 3 (15%) and 4 (8%) were isolated as white solid.
- Example 2 The following illustrate representative pharmaceutical dosage forms, containing a compound of formula I ('Compound X'), for therapeutic or prophylactic use in humans.
Abstract
The invention provides a compound of formula (I) wherein R1-R3 have any of the values defined in the specification, or a salt thereof. The compounds modulate the activity of the FGF1R pathway and are useful for treating cancer.
Description
THERAPEUTIC COMPOUNDS FOR THE TREATMENT OF CANCER
Priority of Invention
This application claims priority to United States Provisional Application Number 61/675,232 that was filed on 24 July 2012. The entire content of this provisional application is hereby incorporated herein by reference.
Background of the Invention
One of the hallmarks of cancer is enhanced growth capacity. A major mechanism
contributing to rapid cellular proliferation is hyperactivation of receptor tyrosine kinase (RTK) signaling pathways. For instance, aberrant Fibroblast Growth Factor Receptor (FGFR) signaling, a receptor tyrosine kinase pathway is observed in multiple cancers including breast, prostate, ovarian and pancreatic carcinomas. Among breast cancers, up to 10% exhibit increased FGFR signaling and are strongly associated with resistance to standard therapies and poor prognosis (see Turner, N., et al., Cancer Res. 2010, 70, 2085-2094). Multiple studies have demonstrated dependencies of tumor cells on FGFR for survival, suggesting that proteins within this signaling pathway are validated therapeutic targets in many cancers.
However, known small molecule receptor tyrosine kinase (RTK) inhibitors targeting FGFR activity are inadequate due to broad specificity and inhibition of multiple RTKs which may be associated with cytotoxicity and increased side effects in patients. Therefore, there is a critical need to identify new compounds with high specificity for the FGFR signaling pathway that are tolerated by normal cells without side effects. Natural products represent a validated source of structurally diverse and biologically active compounds that have been historically successful as anti-cancer agents and cellular tools: for example, rapamycin, an immunosuppressant obtained from Streptomyces hygroscopicus is also a potent anticancer agent which acts by specifically inhibiting mammalian target of rapamycin (mTOR) kinase. There is a need for new therapeutics for FGF dependent carcinomas.
Summary of the Invention
A whole animal in vivo screen for FGF signaling modulators using a larval zebrafish tail regeneration system has been developed. Using this assay, a novel polyketide natural product, colomitide C (1) that inhibited regeneration of tail fins (an FGFR-dependent process) and was nontoxic towards the larvae was identified. The compound is produced in high concentrations through fermentation of the fungus (Cadophora luteo-olivaced) and gram quantities can be easily isolated. Colomitide C was also tested in a 3-D "mammosphere assay" with mammary epithelial
cells isolated from a transgenic mouse in which FGFR1 activation can be induced. In this experiment, treatment with colomitide C prevented the transformation of normal cells into a
"tumorsphere." Additionally, treatment of two-week old tumorspheres with colomitide C resulted in the reversal of the transformation process and return to the smaller, hollow "normal" mammosphere state within one day. Staining studies with labeled cellular markers showed that colomitide C treatment leads to upregulation of apoptosis in FGFR activated cells. Pharmacokinetic studies demonstrated that colomitide C is stable in both blood plasma and liver microscomes.
Accordingly the invention provides a compound of formula I:
wherein:
R1 is (C]-C6)alkyl, (C2-C6)alkenyl, or (C C6)alkynyl, wherein each (C1-C6)alkyl, (C2- C6)alkenyl, and (Q-C^alkynyl is optionally substituted with one or more groups independently selected from halo, (Ci-C^alkoxy, (C1-C6)alkoxycarbonyl, and (C1-C6)alkanoyloxy;
R2 is H and R3 is -ORa or -NRbRc; or R2 and R3 taken together are oxo (=0), or =NRd;
Ra is H or (d-C^alkanoyl;
Rd is hydroxy, (C!-C )alkoxy, -NRbRc, or (C1-C6)alkanoyloxy, wherein the (C1-C6)alkoxy and (C!-C6)alkanoyloxy are each optionally substituted with one or more groups independently selected from halo, (Q-C^alkoxy, (C1-C6)alkoxycarbonyl, aryl, and (C1-C6)alkanoyloxy, and wherein each aryl is optionally substituted with one or more groups independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifiuoromethoxy, (C1-C6)alkoxy, (Q-C^alkoxycarbonyl, and (Ci- C6)alkanoyloxy;
or a salt thereof.
The invention also provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
The invention also provides a method for treating or preventing cancer in an animal comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to
the animal.
The invention also provides a method for modulating the FGF1R pathway in a cell comprising contacting the cell with a compound of formula I or a salt thereof.
The invention also provides a method for treating a pathological condition associated with the FGF1R pathway in an animal comprising administering a compound of formula I or a
pharmaceutically acceptable salt thereof to the animal.
The invention also provides a compound of formula I or a pharmaceutically acceptable salt thereof for use in medical therapy.
The invention also provides a compound of formula I or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of cancer.
The invention also provides a compound of formula I or a pharmaceutically acceptable salt thereof for prophylactic or therapeutic treatment of a condition associated with the FGF1R pathway.
The invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof to prepare a medicament for treating cancer in an animal (e.g. a mammal such as a human).
The invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof to prepare a medicament for treating a pathological condition associated with the FGF1R pathway in an animal (e.g. a mammal such as a human).
The invention also provides a whole animal in vivo screen for FGF signaling modulators using a larval zebrafish tail regeneration system as described herein.
The invention also provides processes and intermediates disclosed herein that are useful for preparing a compound of formula I or a salt thereof.
Brief Description of the Figures
Figure 1: Larvae fin amputation and regeneration (A) Normal larvae fin at 4 days post fertilization. (B) Amputation is performed at the bold vertical line red line. (C) Normal larvae fin at 6 days post fertilization. (D) Regenerated larvae fin at 6 days post fertilization, 2 days after amputation. Vertical dotted line indicates the amputated level. In A-D, the shape of the fin is outlined by a curved dotted line.
Figure 2: Images of regenerating fins after treating with DMSO (A, Control) and BIO (B). Dotted and solid vertical lines represent the amputation plane and the distal edge of the regenerating fin, respectively. Horizontal arrows represent the length to be measured.
Figure 3: Colomitide C can reverse the proliferative phenotype in iFGFRl mammary epithelial cells. A) The iFGFRl transgenic mouse model in which FGFR1 can be induced by a dimerizer AP20187. This results in the FGFR1 kinase domains to dimerize and activates its downstream signal transduction which results into enhance proliferation of the mammary epithelial cells. B) In presence of the dimerizer, mammary epithelial cells from iFGFRl transgenic mice undergo uncontrolled proliferation. Colomitide C can effectively prevent the uncontrolled proliferation as seen in this mammosphere assay.
Figure 4: shows that Colomitide C can inhibit proliferation and induce apoptosis in iFGFRl mammary epithelial cells. The top panel shows the total number of iFGFRl cells seen by using a using a dye (Hoechst33342) that has been untreated or treated with Colomitide C. While all four untreated iFGFRl cells can take up EdU, which suggests that they are proliferating, only 2 out of 20 iFGFRl cells treated with Colomitide C are shown to take up EdU, suggesting that majority of these cells are not proliferating following the treatment of Colomitide C (middle panel). Also, most of the Colomitide C treated iFGFRl cells are shown to undergo apoptosis as shown by TUNEL assay, while none of the control untreated cells are undergoing apoptosis.
Figure 5: Colomitide C inhibits phosphorylation of AKT and affects the downstream targets of AKT signaling pathway. Western analysis of phospho ERK, ERK , phospho-AKT, AKT, phospho-GSK3 β and GSK3 β in iFGFRl mammary epithelial cells.
Figure 6: Colomitide C can inhibit proliferation and induce apoptosis in human breast cancer cell lines. Three breast cancer cell lines, MDA-MB-361, CAMA1 and HCC38 were treated with or without Colomitide C and tested for proliferation (EdU incorporation) and apoptosis (TUNEL). For each cell line, there is a significant loss of proliferation (as shown by almost 100% reduction in EdU uptake) and increased apoptosis (as shown by significant increase in TUNEL staining) following Colomitide C treatment.
Figure 7: Colomitide C targets phosphorylation of AKT in HCC38 human breast cancer cells.
A known inhibitor SU5402 is used as a control.
Detailed Description
The following definitions are used, unless otherwise described: halo is fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as propyl embraces only the straight chain radical, a branched chain isomer such as isopropyl being specifically referred to. Aryl denotes a phenyl radical or an ortho-
fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic.
Specific values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents.
Specifically, (Ci-C^alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl; (C1-C6)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso- butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy; (C2-C6)alkenyl can be vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1- hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl; (C2-C6)alkynyl can be ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1- hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, or 5-hexynyl; (Q-C^alkanoyl can be acetyl, propanoyl or butanoyl; (C1-C6)alkoxy-carbonyl can be methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, or hexyloxycarbonyl; (C2-C6)alkanoyloxy can be acetoxy, propanoyloxy, butanoyloxy, isobutanoyloxy, pentanoyloxy, or hexanoyloxy; and aryl can be phenyl, indenyl, or naphthyl.
In one embodiment, the compound of formula I is a compound of formula (la):
In one embodiment, the compound of formula I is a compound of formula (lb):
In one embodiment, the compound of formula I is a compound of formula (Id):
In one embodiment, the compound of formula I is a compound of formula (Ie):
In one embodiment, R1 is 1-methylpropyl.
In one embodiment, R2 is H and R3 is -OH or NH2.
In one embodiment, R2 and R3 taken together are oxo (=0).
In one embodiment, R2 and R3 taken together are =NRd.
In one embodiment, Rd is hydroxy.
In one embodiment, Rd is (C1-C6)alkoxy optionally substituted with one or more groups independently selected from halo, (CrC6)alkoxy, (CrC^alkoxycarbonyl, aryl, and (Ci-
C6)alkanoyloxy, wherein each aryl is optionally substituted with one or more groups independently selected from halo.
In one embodiment, Rd is (C1-C6)alkanoyloxy, optionally substituted with one or more groups independently selected from halo,
C6)alkanoyloxy, wherein each aryl is optionally substituted with one or more groups independently selected from halo.
In one embodiment, Rd is benzyloxy, phenylcarbonyloxy, amino, or a-trifluoromethyl-a- methoxybenzyl.
In one embodiment the compound of formula I is not colomitide C. In another embodiment the invention provides colomotide C in isolated or purified form (e.g. at least about 80, 90, 95, or 99% pure).
In one embodiment the compound of formula I is not colomitide A. In another embodiment the compound of formula I is not colomitide B. In one embodiment the compound of formula I is not colomitide A or colomitide B. In one embodiment the compound of formula I is not colomitide A, colomitide B or colomitide C.
Processes and intermediates useful for preparing compounds of formula I are provided as further embodiments of the invention and are illustrated by the following procedures in which the meanings of the generic radicals are as given above unless otherwise qualified.
An intermediate useful for preparing a compound of formula I, is a compound of the following formula
Another intermediate useful for preparing a compound of formula I, is a compound of the following formula
An intermediate useful for preparing a compound of formula 1(b), is a compound of the following formula
An intermediate useful for preparing a compound of formula 1(c), 1(d) or 1(e), is a compound of the following formula
It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by
recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase. When a compound is shown with a wedged (up) or dashed (back) bond the compound may be enriched by about 60%, 80%, 90%, 95%, 98%, or 99% in the absolute stereoisomer represented.
In cases where compounds are sufficiently basic or acidic, a salt of a compound of formula I can be useful as an intermediate for isolating or purifying a compound of formula I. Additionally, administration of a compound of formula I as a pharmaceutically acceptable acid or base salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate, and a- glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
The compounds of formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid
carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.
The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying
techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as
compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
Examples of useful dermatological compositions which can be used to deliver the compounds of formula I to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No.
4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
Useful dosages of the compounds of formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
The biological activity of a compound of the invention may be determined using pharmacological models which are well known to the art, or using Test A described below.
Test A Fin Regeneration Assay
Regeneration of the tail fin of zebrafish larvae was used as one of biological assays. The assay was a modification of a procedure reported by Kawakami A, et al., Dev Dyn. 2004, 231(4): 693-699.
Zebrafish housing, mating, embryo collection, and raising larvae are performed by following standard procedures in the Zebrafish Book (Westerfield, M. (2000). The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio). 4th ed., Univ. of Oregon Press, Eugene). Zebrafish larvae used in the assay were not given any food during the assay period (up to 6 days post fertilization). Embryos and larvae were developed at 28°C in the embryo media. For anesthetizing, approximately 1% volume of tricaine (MS-222) solution (40 mg/ml) was added to larvae.
After anesthetizing larvae at four-day post fertilization, a larva was placed on a transparent plastic dish, and associated liquid was removed by absorbing it using Kimwipe, so that the larva attached to the dish. Under a stereomicroscope, the tail was cut with a razor blade at the immediately caudal level of the neural tube (Fig. 1). The cutting was made perpendicular to the neural tube.
Five larvae were placed in one well of a 24-well tissue culture plate. The media in a well was removed without disturbing larvae, and 1 ml of new embryo media was added to the well. A compound, which was dissolved in dimethyl sulfoxide (DMSO), was added to the 1 ml media with five larvae. Depending on the concentration of the stock solution of the compound, and depending on the final concentration to be tested, the volume of compound added to the 1ml media was changed. In a standard assay, the volume of compound solutions or DMSO was 10 ul, and the maximum volume of the compound solution in some assays was 20 ul. Ten ul of 500 nM BIO in DMSO was added to a well as a control (BIO: 6-Bromoindirubin-3'-oxime, CAS Number: 667463-62-9). The solution was mixed by pipeting without disturbing larvae.
After one-day treatment, media was removed and new media (1 ml) was added to each well. The same compound was added at the same concentration. One day later (total two days of treatment, larvae are now at 6 days post fertilization), larvae were anesthetized by adding tricaine solution into the well. A picture of the larva fin was taken by using Zeiss V8 Discovery stereomicroscope with Plan S l.Ox objective lens, Jenoptik Progress C3 camera and iSolution light software. The
magnification of the Zeiss V8 Discovery stereomicroscope was x8.
The longest length of regenerated area was determined by i Solution software by measuring the pixel number of the line that was drawn perpendicular to the amputation plane (Fig. 2). The average of regenerated lengths of the control group was set as 1.00, and regenerated length of each larva was calculated. The regenerated length by treating larvae with a compound was evaluated in comparison to a control group, and statistical significance was determined by Student's t-test. If the p value was smaller than 0.05, it was considered that the compound has significant activity of either enhancing or inhibiting regeneration. If more than three larvae of a control group (treated by DMSO) were dead, it was considered that the quality of the larvae of the specific batch was bad, and the entire data of the assay was not used to evaluate any compound in the assay.
BIO has been shown to impair larvae fin regeneration in a similar, but not identical assay (Lijoy K. Mathew, et al., FASEB J. 2008 August; 22(8): 3087-3096). Thus, if larvae treated by BIO did not show statistically significant inhibition of fin regeneration, it was considered that the quality of the larvae of the specific batch was bad, and the entire data of the assay was not used to evaluate any compound in the assay. If more than three larvae of a treated group were dead, the compound in the assay was not evaluated.
The biological activity of a compound of the invention may also be determined using pharmacological models which are well known to the art, or using Test B described below.
Test B Activity of colomitide C on larvae fin regeneration
Colomitide C was tested for the fin regeneration assay. As shown in Table 1, at 10 ug/ml, colomitide C inhibited fin regeneration. The degree of regenerated lengths was 74.8±1.9%, compared to DMSO treated control larvae.
Table 1 Assay results for different concentrations of Colomitide C
Measurement value (pixel) Relative length of the regenerated area P
#1 #2 #3 #4 #5 ave. SD #1 #2 #3 #4 #5 ave. SD value
1% DMSO 60.8 63 63.1 57 0 60.98 2.85 0.997 1.033 1.035 0.935 1.000 0.047
BIO (0.5 nM) 40 51.6 41 47 0 44.90 5.43 0.656 0.846 0.672 0.771 0.736 0.089 0.004
Colomitide C
(1 ug/ml) 61.4 57.2 63 69.1 0 62.68 4.93 1.007 0.938 1.033 1.133 1.028 0.081 0.578
Colomitide C
(5 ug ml) 55 54 52 62.2 0 55.80 4.45 0.902 0.886 0.853 1.020 0.915 0.073 0.106
Colomitide C
(10 ug/ml) 38 58 49 44.3 44 46.66 7.44 0.623 0.951 0.804 0.727 0.722 0.765 0.122 0.009 value 0 indicates that the animal was dead. This value is not integrated in
calculation
Activity of benzyl-colomitide C on larvae fin regeneration
Benzyl-colomitide C was tested in the larvae fin regeneration assay. As shown in Table 2, it showed toxicity at 10 ug/ml. However, as shown in Table 3, at lower concentrations, it exhibited an inhibitory activity on fin regeneration.
Table 2 Comparison of activity of Colomitide C and benzyl-colonitide C at 10 ug/ml
Measurement value (pixel Relative length of the regenerated area
P"
#1 #2 #3 #4 #5 ave. SD #1 #2 #3 #4 #5 ave. SD value
DMSO 45.10 61.20 47.54 57.31 65.00 55.23 8.62 0.817 1.108 0.861 1.038 1.177 1.000 0.156
BIO 29.50 39.00 29.12 28.84 0.00 25.29 14.77 0.534 0.706 0.527 0.522 0.572 0.089 0.002
Colomitide C.
(10 ug/ml)
39.56 38.28 40.00 18.97 42.01 35.76 9.48 0.716 0.693 0.724 0.344 0.761 0.648 0.172 0.009
Benzyl
colomitide
(10 ug/ml) 0.00 0.00 0.00 0.00 0.00
value 0 indicates that the animal was dead. This value is not integrated in
calculation
Table 3 Activity of benzyl-Colonitide C at concentrations lower than 10 ug/ml
Measurement value (pixel) Relative length of the regenerated area
P~
#1 #2 #3 #4 #5 ave. SD #1 #2 #3 #4 #5 ave. SD value
DMSO 44.01 42.05 41.44 0.00 0.00 42.50 1.35 1.036 0.989 0.975 1.000 0.032
BIO 34.44 41.63 33.62 32.02 0.00 35.42 4.26 0.810 0.980 0.791 0.753 0.834 0.100 0.042
Benzyl colomitide
( 1 ug/ml) 37.20 38.64 38.60 0.00 0.00 38.15 0.82 0.875 0.909 0.908 0.898 0.019 0.009
Benzyl colomitide
(3 ug/ml) 36.24 38.12 38.95 36.14 0.00 37.36 1.40 0.853 0.897 0.916 0.850 0.879 0.033 0.005
Benzyl colomitide
(5 ug/ml) 32.25 31.95 35.44 31.78 33.00 32.88 1.50 0.759 0.752 0.834 0.748 0.777 0.774 0.035 0.000
value 0 indicates that the animal was dead. This value is not integrated in
calculation
Mammary Mammosphere Assay:
To test whether Colomitide C can have any effect on specific signaling pathways which are found to be upregulated in cancer, a mouse model system where the FGFRl signaling pathway can be induced via a FGFRl dimerizer, AP20187 was used. Upregulation of FGFRl in the mammary epithelial cells results into uncontrolled proliferation of these cells which can be assayed by transformed acinar structure in the matrigel (Figure 3 A). As shown in the figure 3, Colomitide C can prevent the transformation of these cells upon FGFRl activation. Additionally, it can reverse the phenotype when applied to the FGFRl mediated transformed acinar structures. These data suggest that Colomitide can potentially inhibit RTK pathways, like FGFRl upregulation.
Colomitide C can inhibit proliferation and induce apoptosis in iFGFRl mammary epithelial cells
To understand how Colomitide C can inhibit transformation of iFGFRl mammary epithelial cells, proliferation and apoptosis assays of these cells in presence and absence of Colomitide C was carried out. As shown in Figure 4, Colomitide C can inhibit the iFGFRl mammary epithelial cells to incorporate 5-ethynyl-2'-deoxyuridine (EdU), which suggest that Colomitide C inhibits proliferation of these cells. More strikingly, TUNEL assay shows that iFGFRl mammary epithelial cells undergo apoptosis in presence of Colomitide C when FGFR1 is upregulated (Figure 4).
Colomitide C affects AKT phosphorylation in iFGFRl mammary epithelial cells
To identify which arm of the FGFR1 pathway is affected by Colomitide C, analysis of the downstream targets of FGFR1 was carried out.
GFR1 can mediate activation of several sinaling pathways, including induction of ERK1/2 and AKT signaling pathways. These are marked by phosphorylation of the ERK1/2 and/or AKT. Aberrant phosphorylation of these two proteins are found in many cancers. Western analysis of these two proteins was carried out. Whereas phosphorylation of ERKl/2 remains unaffected,
phosphorylation of AKT is reduced in presence of Colomitide C, suggesting that Colomitide C acts specifically in the AKT pathway in the iFGFRl mammary epithelial cells (Figure 5). This is further evident from the fact that phosphorylation of GSK3P, a direct target of AKT, is markedly reduced in these iFGFRl cells (Figure 5).
Colomitide C can inhibit proliferation and induce apoptosis in human breast cancer cells
To examine whether Colomitide C can have therapeutic potential in human cancers, its effect on the proliferation in the human breast cancer cell lines, MDA-MB 361, CAMA 1, and HCC 38 was examined. All these cell lines are known to have aberrant FGFR signaling. Following 24 hours treatment with the Colomitide, all the three breast cancer cell lines have dramatic reduction in proliferation and induction of apoptosis, as seen previously in the iFGFRl mammary epithelial cells (Figure 6). This is a proof of principle that Colomitide C can have potent anti-cancer therapeutic properties. Additionally, the AKT phosphorylation was reduced in the Colomitide C treated HCC38 cells, suggesting that for this breast cancer cell line, Colomitide C is likely affecting the AKT signaling pathway (Figure 7). The above experiments provide strong proof of principle that
Colomitide C can have anti-cancer activity and can be of therapeutic value.
The invention will now be illustrated by the following non-limiting Examples.
Examples
Example 1.
A. Fungal Fermentation and Extraction
The strain was cultured in 20 erlenmeyer flask containing 100 g rice media at room temperature. After 30 days, the culture was extracted with two times 4 liters of methanol and two times 4 liters of ethylacetate, consecutively. The extracts were combined and dried in the vacuum. Dried extract was suspensed in 500 ml of water and then partitioned with 500 ml of ethylacetete. Dried ethylacetate extract was then dissolved in 500 ml of 90 % methanol (v/v in water) and extracted with 250 ml of n-hexane. Methanol extracts (later called as ethylacetate extracts) was dried and further processed for the isolation of colomitide C (1)
B. Isolation of Colomitide C (1)
7.8 g of crude ethylacetate extract was separated using ISCO® flash chromatography with 50 g silica as stationary phase and linear gradient elution of 100 % to 0 % of CH2Cl2/MeOH. Fraction 24 (5.4 g) was then further chromatographed using ISCO® flash chromatography with 50 g silica as mobile oil phase and linear gradient elution of 100 % to 0 % of n-hexane/ethylacetate. Colomitide C (1) (fraction 37 ; 1802.8 mg) was isolated as yellowish clear oil. The next fractions (called fraction 24.53 ; 3324.5 mg)was re-separated using 50 g silica with linear gradient elution of 100 % to 0 % of n-hexane/ethylacetate to obtain more colomitide C (1) (970.2 mg). Total colomitide C (1) isolated from this culture was 2773 mg.
<¾ (J in Hz) *■ COSY HMBC ROESY
H to H H to C H to H
1 214.8
2 2.83 q (6.6) 41.2 3A, 3B, 5 1, 3, 4, 5 5', 4
3 A 1,65 m 26.5 2, 13B, 4 1, 2, 4, 5 4', 5
B 1.37 m 2, 3A, 4 1, 2, 4, 5 4',5
4 0.86 1 (7.2) 10.5 3A/B 2, 3 8', 2
5 1.04 d (6.6) 15.3 2 1, 2, 3 5', 4', 3A/B
1' 108.6,
3' A 4.04 d (12.0) 58.6 4',3'B 1', 5', 4', 1
B 3.83 dd (12.0, 4.8) 4', 3Ά 1
4' 2.78 dd (4.8, 3.5) 52.5 5', 3Ά/Β 8', 5' 6'B, 3A, 3B, 5
5' 2.71 dd (4.2, 3.5) 41.9 4', 6Ά/Β l'(weak), 3' 6Ά, 2, 8', 5, 8'-Me
(weak)
6' A 4.17 dd (8.4, 4.2) 71.0 5', 6B 6', 4' 5', 8'-Me
B 4.00 d (8.4) 5', 6A 1' (weak), 8', 4' 4'
8' 1.81 q (7.2) 42.4 8'-Me 1 (weak), 5',4', 6', 5', l'-Me, 5, 8'-Me
8'-Me
l'-Me 1.27 s 19.0 1', 8'
8'-Me 0.90 d (7.2) 12.0 8' 1', 8', 5'
C. Reduction of colomitide C
Colomitide C (1) (28 mg ; 0.12 mmol) and cerium chloride heptahydrate (92 mg ; 0.32 mmol) were dissolved in 1 ml methanol. While stirring at 0°C, sodium borohydride (9.3 mg ; 0.24 mmol) was added into solution and the reaction was continued at 0°C for 1 hr. After the mixture was kept at -20° C for 24 hr, it was then dried out and portioned between water and EtOAC. Ethylacetate fraction (25.6 mg) was then subjected to a separation using preparative HPLC with gradient elution 35% - 100 % of acetonitrile/H20. Three isomers of products 2 (70 %), 3 (15%) and 4 (8%) were isolated as white solid.
Structure of 2, 3 and 4
Table 2. NMR data of 2 (CD3OD, 600 MHz)
Position ¾ (./ in Hz) £&mult. COSY HMBC NOESY
(H to H) (H to C)
1
1 3.74 d (9.4) 71.3 2 4', 2' 5 8', 3'B, 2, 3 A
2 1.48 m * 37.1 3A/B, 5 3 1, 4', 5
3 A. 1.48 m * 27.1 3B, 2, 4 2, 5 10, 6B, 13, 14*
B. .35 m 3A, 2, 4 1 2, 5 3A
4 0.95 t (7.0) 21.6 3A/B 2, 3 1, 4'
5 0.80 d (6.3) 11.2 2 1, 2, 3A/B 4', 2
1' 108.3
3' A. 3.87 dd (12.5 ; 5.1) 60.7 4', 3B' 5', 1' 4'
B. 3.45 d (12.5) 4', 3Ά 1', 5', 4', 1 4', 1, 3A
4' 1.72 br 43.1 5', 3Ά/Β, 1 1 3Ά/Β, 1, 5', 2, 4, 5
5' 2.60 br 41.8 6A, 4' 3' 6Ά, 8', 4', 8'-Me
6' A. 4.13 dd (8.0 ; 5.0) 71.9 5', 6B 4' 5', 8'-Me
B. 3.89 d (8.0) 6A Γ, 4'
8' 2.23 q (7.0) 40.4 8'-Me 5', 8'-Me 1, 5", l'Me, 8'-Me
8'-Me 1.30 s 18.9 1', 8' 1', 3'
r-Me 0.93 d (7.0) 13.0 7 Ι', 8', 5' 6A, 8', 5'
Table 3. NM data of 3 (CD3OD, 600 MHz)
Position <¾ (J in Hz) Samu\t. COSY HMBC NOESY
(H to H) (H to C)
1 3.64 d (9.7) 74.2 4' 3 , 3, 5 8 , 3 , 2, 5
2 1.53 m 36.2 5 8', 5', 5
3 A. 1.42 m 20.4 3B, 4 2, 4, 5 5'
B. 1.11 m 3A, 4 2, 4, 5
4 0.93 t (7.5) 11.1 3 A/B 2, 3 3A/B
5 1.01 d (6.6) 15.8 12 1, 2, 3 1, 3A
1' 108.3
3' A. 3.87 bs 61.0 4', 3'B 4' 4'
B. 3.87 bs 4', 3Ά 1', 5', 4', 1 4'
4' 1.62 m 43.6 5', 3Ά/Β, 1 3A
5' 2,17 (7.0 ; 4.0 ; 3.1) 42.5 4', 6Ά 1, 8', 4', 8'- (3Ά/Β, 6'B)**, 6Ά, 8'-Me, 2, 3A
Me, 3'
6' A. 4.12 dd (8.4 ; 4.4) 71.8 4', 5', 6'B 1', 8', 5', 4' 5', 8'-Me
B. 3.90 d (8.4) 6Ά 1', 8', 4', 5' 4', 5'
7' 1.98 q (7.0) 41.1 8 Γ, 5', 8'- 8'-Me, l'-Me, 1
Me, 6'
l'- e 1.30 s 19.2 l'-Me, 8' 8', 8'-Me
8'-Me 0.89 d (7.0) 13.3 3 1', 8', 5' 8'. 5', 6Ά
Table 4. NMR data of 4 (CD3OD, 600 MHz)
Position <¾ (J in Hz) (¼,mult. COSY HMBC NOESY
(H to H) (H to C)
1 3.51* 74.4 4' 5', 3, 2, 3 6Ά
2 1.49 q (7.5) 35.6 5 3, 5 1/3'A„ 5
3 A. 1.43 m 26.7 3B, 4 1„ 2, 4, 5 5, 9A, 11
B. 1.33 m 3A, 4 1„ 2, 4, 5 8'-Me, 5
4 0.89 t (7.0) 12.4 2, 3
5 0.86 d (7.5) 13.0 2 1, 2, 3 4'
1' 107.5
3' A. 3.51* 62.2 3'B, 4' 5', 1 4', 6' A, 2
B. 3.31** 3Ά, 4' 5'
4' 1.91 br 45.4 3Ά/Β, 1 8', 3' 8', 5', 3'A/l, 5
5' 2.39 br 43.5 1', 8', 4', 1 4', 8'-Me, 6Ά/Β
6' A. 4.15 d (8.2) 68.1 6'B 1, 8', 4', 5' 1, 3'B
B. 3.87 dd (8.2 ; 4.7) 5', 6Ά 4' 5', 8'-Me
8' 1.77 q (7.0) 48.0 8 4', 5', l'-Me, 8'-Me l'-Me 1.28 s 20.3 1', 8' 8'
8'-Me 0.95 d (7.0) 14.2 8, 1', 8', 5'
D. Preparation of oxime derivates of colomitide C
A mixture of 500 mg (2.2 mmol) of colomitide C (1), 2 ml (7.5 mmol) of triethanolamine and 0.2 ml (3.66 mmol) NH2OH (50 % w/w in water) were dissolved in 15 ml MeOH. The mixture was refluxed for 24 hours. The reaction mixture was then dried and partitioned between water and EtOAc. Ethylacetate fraction were then subjected to separation using ISCO® flash chromatography with 40 g silica as mobile
phase and linear gradient elution of 100 % to 0 % of CH2Cl2/MeOH. Two isomers, 5 (80 %) and 6 (12%) were purified as white solids.
Structure of 5 and 6
Table 5. NMR data of 5 (CD3CN, 600 MHz)
Position <¾ (J in Hz) S0mu\X. COSY HMBC NOESY
(H to H) (H to C)
1 163.6
2 2.76 m 37.7 5 1, 3, 4, 5, 4' 5, 4
3 A. 1.77 m 27.6 4 1, 2„ 4, 5
B. 1.47 m 4 1, 2, 4, 5
4 0.90 1 (7.0) 13.4 3A/B 2, 3 2
5 1.14 d (7.1) 16.7 2 2, 3 2, 4', 5'
1' 109.8
2'
3' A. 3.88 d (11.7) 62.0 3'B. 4 1, 1', 4', 5'
B. 3.87 dd (11.7 ; 6.0) 3'A, 4 1, i'
4' 2.52 br 45.6 3Ά/Β, 5' 1', 3', 5', 6' 5
5' 2.42 br 44.4 4', 6Ά 1', 3', 4', 8'-Me 5, 8'-Me
6' A. 4.11 dd (8.2 ; 4.7) 73.0 5', 6'B 1', 4', 5' 8'-Me, 4', 5'
B. 3.92 d (8.2) 6Ά 1', 4', 5', 5'
7 /'
8' 2.20 m 41.9 8'-Me V, 4', 5', 6', 8'- 8'-Me
Me
l'-Me 1.26 s 21.0 1', 8'
8'-Me 0.87 d (7.0) 14.5 8' 1', 5', 8'
1-NOH 8.40 s
Table 6. NM data of 6 (CD3CN, 600 MHz)
Position 4 (J in Hz) <5t,mult. COSY HMBC NOESY
(H to H) (H to C)
1 163.6, C
2 3.00 q (7.0) 35.7, CH 5 1, 3, 4, 5, 4', 5
3 A. 1.53 m 27.6, CH2 3B, 4 1, 2, 4, 5
B. 1.43 m 3A, 4 1, 2, 4, 5
4 0.82 1 (7.0) 13.1, CH3 3A/B 2, 3
5 1.05 d (7.0) 17.0, CH3 2 1, 2, 3 2, 4'
1' 108.6, C
2'
3' A. 3.82, t (11.1 ) 63.9, CH2 3Ά 1, 1', 4', 5' 4'
B. 3.60, dd (11.1 ; 5.3) 3'B, 4' 1', 4', 5'
4' 2.71, dd (11.1 ; 5.3) 43.1, CH 3Ά/Β 1, 2, 3', 5', 6' 5, 3Ά/Β, 5', 8',
5' 2.27, d (3.5) 45.7, CH 6Ά/Β 1, 1', 3', 4',8', Me-8' 5, 6Ά/Β, 8', Me-8'
6' A. 4.21, d (8.2) 68.9, CH2 5', 6'B 1', 4', 5', 8' 5'
B. 3.84, dd (8.2 ; 3.5) 5', 6Ά 4', 5', Me-8'
7 /'
8' 1.90 q (7.0) 48.4, CH Me-8' 1', 4', 5', 6', Me-8' 4'
Me-1' 1.26 s 20.6, CH3 1', 8'
Me-8' 0.91, d (7.0) 15.1, CH3 8' 1', 5', 8' 4',5', 8', 6'B
NOH-1 8.33 s
Preparation of benzyl oxime of colomitide C A mixture of 16.2 mg (0.067 mmol) of oxime derivate (5) of colomitide C and 10 mg (0.4 mmol) of NaH were dissolved in DMF and cooled in ice bath for 30 minutes. To the mixture was added 40 μΐ (0.33 mmol) benzylbromide and kept at 0°C for 1 hour. The reaction was continued at room temperature for 24 hours. The reaction mixture was then dried out under vacuum and portioned between EtOAc and water. EtOAc fraction was subjected to separation using silica column with mobile phase 98 : 2 (CH2Cl2/MeOH). Benzyl oxime derivate (7) of colomitide was isolated as clear oily compound (60%).
Structure of 7 Table 7. NMR data of 7 (CD3OD, 600 MHz)
Position 4 (J in Hz) c,mult. COSY HMBC NOESY
(H to H) (H to C)
1 163.6
2 2.64 q (7.0) 38.8 3A/B, 5 1,3, 4, 5, 4' 5, 5'
3 A. 1.74 m 27.6 2, 3B, 4 1, 2, 4, 5 4
B. 1.44 m 2, 3A, 4 1, 2, 4, 5 4
4 0.84 1 (7.1) 13.9 3A/B 2, 3 3A/B
5 1.10 d (7.0) 16.5 2 1, 2, 3
1' 110.2
2'
3' A. 3.95 d (11.2) 62.1 3'B, 4 1, 1', 5'
B. 3.83 dd (11.2 ; 5.3) 3Ά, 4 1, 1',
4' 2.49 bs 46.0 3Ά/Β, 5' 1, 5', 6', 8' 5, 6Ά
5' 2.35 bs 44.3 4', 6Ά/Β Γ, 3', 8'-Me 5, 8'-Me
6' A. 4.11 dd (8.3 ; 4.7) 72.8 5', 6'B l', 4\ 5' 4', 8'-Me
B. 3.94 d (8.3) 5;, 6Ά 1', 4', 5', 8'
7 /'
8' 2.15 q (7.0) 41.6 8'-Me 1', 4', 5', 6', 8'-Me 8'-Me
l'-Me 1.28 s 20.2 1', 8'
8'-Me 0.79 d (7.0) 12.8 8' 1', 5', 8' 6Ά
1" 140.0, C
2"/6" 7.37 d (7.0) 129.6, CH 375" 2"/6". 4", 7" 7"
375" 7.32 dd (7.1 , 7.0) 128.9, CH 2", 4"/ 6", 1", 3"/5"
4" 7.27 t (7.1) 128.7, CH 3", 5" 2"/6"
7" A/B 5.04 d (4.7) 76.6, CH2 1", 2"/6" 6Ά/Β, 7"
E. Preparation of p-bromobenzoyl oxime of colomitide
To a stirring solution of 7 mg (0.03 mmol) of oxime form (5) in 4 ml CH2C12 in ice bath, 7.3 mg (0.06 mmol) of dimethylaminopyridine and 4.8 μΐ (0.06 mmol) of pyridine were consecutively added. The
reaction mixture was kept at 0°C for 30 minutes after addition of 13 mg (0.06 mmol) of p-bromobenzoyl chloride. The reaction was continued at room temperature for 24 hours before evaporation under vacuum and partition between water and EtOAc. EtOAc fraction was then subjected to separation using preparative HPLC (CI 8 column) with gradient elution of 50 % to 100 % acetonitrile/H20. Benzoyl oxime derivate (8) was isolated as white solids (yield 72 %).
Structure of 8
Table 8. NMR data of 8 (CD3OD, 600 MHz)
Position (J in Hz) <5 mult. COSY HMBC NOESY
(H to H) (H to C)
1 174.4,
2 2.83 m 39.6, 3A/B, 5 1, 3, 4, 5, 4' 4', 5', 5
3 A. 1.78 m 27.4, 3B, 2, 4 1, 2, 4, 5 4
B. 1.58 m 3A, 2, 4 1, 2, 4, 5 4
4 0.93 t (7.2) 13.9, 3A/B 2, 3 5
5 1.25 d (7.3) 16.7, 2 1, 2, 3
1' 109.5
3' A. 4.02 d (11.9) 61.0 3'B, 4' 1, 1'. 4', 5' 4'
B. 3.87 dd (11.9 ; 5.3) 3Ά, 4' 1, 1'. 4', 5' 4'
4' 2.75 bs 46.2, 3Ά/Β, 5' 1, 3', 5', 8', 6'
5' 2.51 bs 43.6, 4', 6Ά/Β 1', 6', 4'. 8'. 8'-Me 5, 8', 8'-Me
6' A. 4.15 dd (8.6 ; 4.6) 72.2 6'B, 5' 1', 8', 4', 5' 5', 8'-Me
B. 3.98 d (8.6) 6Ά, 5' 1', 8', 4', 5' 5', 4'
8' 2.32 q (7.3) 41.5, 8' Me 1', 8'-Me, 6',4', 5', l'-Me 8'-Me
Me-1' 1.28 s 20.4, 1', 8'
Me-8' 0.89 d (7.3) 12.5, 8' 1', 8', 5'
1" 129.4,
2"/6" 7.93 d(7.9) 132.0, 3"/5" 7", 4", 672'
3"/5" 7.71 d(7.9) 132.8, 2", 476", 1", 573"
A"
4" 128.7,
7" 163.8,
F. Preparation of hydrazone derivate of colomitide C
A solution of 22.5 mg (0.1 mmol) of colomitide C and 20 mg (0.4 mmol) of NH2.NH2.H20 in 1.5 ml ethanol was refluxed for 24 hours. The mixture was then dried under vacuum and partitioned with water and ethylacete. Ehylacetate fraction was then separated using silica column with mobile phase 97.5/2.5 =
C reaction.
9 10
Structures of 9 and 10
Table 9. NMR data of 9 (CD3OD, 600 MHz)
Position <¾ [J in Hz) ¾,mult. COSY HMBC NOESY*'
(H to H) (H to C)
1 159,5
2 2.70 m 35.8 1, 3, 4, 5, 4'
3 A. 1.67 m 26.8 1, 2, 4, 5
B. 1.41 m 1, 2, 4, 5
4 0,71 1 (7.0) 12.3 2, 3
5 1.1 d (6.6) 15.4 1, 2, 3
1' 111.3
3' A. 3.86 d (11.7) 62.6 1, l', 4', 5'
B. 3.85 dd (11.7 ; 6.0) 1, 1', 4', 5'
4' 2.60 bs 44.0 1 3Ά/Β, 4, 5
5' 2,40 bs 44,7 1', 6, 4', 8'-Me 6Ά/Β,
6' A. 4.12 dd (8.4 ; 4.7) 72.2 1', 4', 5' 5
B. 3.94 d (8.4) 1', 4', 5'
8' 2.35 q (7.2) 40.8 1', 6', 8'-Me, l'-Me
l'-Me 1.30 s 19.8 1', 8'
8'-Me 0.86 d (7.2) 13.7 1', 5', 8'
Table 10. NMR data of 10 (CD3OD, 600 MHz)
Position <¾ (-/ in Hz) 80mu\X.. COSY HMBC NOESY*'
(H to H) (H to C)
1 159.4
2 2.45 m 41.0 1, 3, 4, 5
3 A. 1.64 m 30.0 1, 2, 4, 5
B. 1.45 m 1, 2, 4, 5
4 1.09 d (7.0) 21.8 2, 3
5 0.91 1 (7.3) 13.0 1, 2, 3
Y 110.2
3' A. 3.99 d (11.7) 61.0 1, 5' 4'
B. 3.95 dd (11.7 ; 6.0) 1, 1', 5' 4'
4' 2.72 dd (3.3 4.4) 44.1
5' 2.67 bs 43.8
6' A. 4.14 dd (8.2 ; 4.8) 73.0 1', 4' 4'
B. 3.97 d (8.2) 1', 4' 4'
8' 1.94 q (6.7) 44.2 6', 4'
l'-Me 1.33 s 21.0 1', l'-Me
8'-Me 0.88 d (6.7) 14.8 l', 5'
Example 2. The following illustrate representative pharmaceutical dosage forms, containing a compound of formula I ('Compound X'), for therapeutic or prophylactic use in humans.
(T) Tablet 1 mg/tablet
Compound X= 100.0
Lactose 77.5
Povidone 15.0
Croscarmellose sodium 12.0
Microcrystalline cellulose 92.5
Magnesium stearate 0
300.0 in) Tablet 2 mg/tablet
Compound X= 20.0
Microcrystalline cellulose 410.0
Starch 50.0
Sodium starch glycolate 15.0
Magnesium stearate 5J0
500.0
(iii) Capsule mg/capsule
Compound X= 10.0
Colloidal silicon dioxide 1.5
Lactose 465.5
Pregelatinized starch 120.0
Magnesium stearate 10
600.0
(iv) Injection 1 (1 mg/ml) mg/ml
Compound X= (free acid form) 1.0
Dibasic sodium phosphate 12.0
Monobasic sodium phosphate 0.7
Sodium chloride 4.5
1.0 N Sodium hydroxide solution
(pH adjustment to 7.0-7.5) q.s.
Water for injection q.s. ad 1
(v) Injection 2 (10 mg/ml) mg/ml
Compound X= (free acid form) 10.0
Monobasic sodium phosphate 0.3
Dibasic sodium phosphate 1.1
Polyethylene glycol 400 200.0
1.0 N Sodium hydroxide solution
(pH adjustment to 7.0-7.5) q.s.
Water for injection q.s. ad 1 mL (vi) Aerosol mg/can
Compound X= 20.0
Oleic acid 10.0
Trichloromonofluoromethane 5,000.0
Dichlorodifluoromethane 10,000.0
Dichlorotetrafluoroethane 5,000.0
The above formulations may be obtained by conventional procedures well known in the
pharmaceutical art.
All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
Claims
1. A compound of formula I:
wherein:
R1 is (C1-C6)alkyl, (C2-C6)alkyl, or (Ci-C6)alkenyl, wherein each (d-C^alkyl, (C2-C6)alkyl, or (C!-C6)alkenyl is optionally substituted with one or more groups independently selected from halo, (Q-C^alkoxy, (Q-C^alkoxycarbonyl, and (C1-C6)alkanoyloxy;
R2 is H and R3 is -ORa or -NRbRc; or R2 and R3 taken together are oxo (=0), or =NRd;
Ra is H or (C1-C6)alkanoyl;
Rb and Rc are each independently selected from H, (C1-C6)alkyl, and (C1-C6)alkanoyl; and Rd is hydroxy, (C1-C6)alkoxy, -NRbRc, or (C1-C6)alkanoyloxy, wherein the (C C6)alkoxy and (Q-C^alkanoyloxy are each optionally substituted with one or more groups independently selected from halo, (Ci-C6)alkoxy, (Q-C^alkoxycarbonyl, aryl, and (d-C^alkanoyloxy, and wherein each aryl is optionally substituted with one or more groups independently selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, (Q-C^alkoxy, (C1-C6)alkoxycarbonyl, and (Q- C6)alkanoyloxy;
or a salt thereof.
or a salt thereof.
or a salt thereof.
or a salt thereof.
5. The compound of claim 1 which is a compound of formula (Id):
or a salt thereof.
6. The compound of claim 1 which is a compound of formula (Ie):
or a salt thereof.
8. The compound of any one of claims 1-6 wherein R1 is 1 -methylpropyl.
9. The compound of any one of claims 1-8 wherein R is H and R is -OH or NH2.
10. The compound of any one of claims 1-4 and 7-8 wherein R2 and R3 taken together are oxo (=0).
11. The compound of any one of claims 1 -4 and 7-8 wherein R2 and R3 taken together are =NRd.
12. The compound of claim 11 wherein Rd is hydroxy.
13. The compound of claim 11 wherein Rd is (C1-C6)alkoxy optionally substituted with one or more groups independently selected from halo, (Q-C^alkoxy, (C1-C6)alkoxycarbonyl, aryl, and (Q- C6)alkanoyloxy, wherein each aryl is optionally substituted with one or more groups independently selected from halo.
14. The compound of claim 11 wherein Rd is
optionally substituted with one or more groups independently selected from halo, (C C6)alkoxy, (C1-C6)alkoxycarbonyl, aryl, and (C1-C6)alkanoyloxy, wherein each aryl is optionally substituted with one or more groups
independently selected from halo.
15. The compound of claim 11 wherein Rd is benzyloxy, phenylcarbonyloxy, amino, or a- trifluoromethyl-a-methoxybenzyl .
16. A pharmaceutical composition comprising a compound as described in any one of claims 1- 15 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
17. A method for treating cancer in an animal comprising administering a compound as described in any one of claims 1-15 or a pharmaceutically acceptable salt thereof to the animal.
18. The method of claim 17 wherein the cancer is breast cancer.
19. A method for modulating the FGF1R pathway in a cell comprising contacting the call with a compound as described in any one of claims 1-15 or a salt thereof.
20. A method for treating a pathological condition associated with the FGF1R pathway in an animal comprising administering a compound as described in any one of claims 1-15 or a
pharmaceutically acceptable salt thereof to the animal.
21. A compound as described in any one of claims 1 - 15 or a pharmaceutically acceptable salt thereof for use in medical therapy.
22. A compound as described in any one of claims 1-15 or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of cancer.
23. A compound as described in any one of claims 1-15 or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a pathological condition associated with the FGF1R pathway.
24. The use of a compound as described in any one of claims 1-15 or a pharmaceutically acceptable salt thereof to prepare a medicament for treating cancer in an animal (e.g. a mammal such as a human).
25. The use of a compound as described in any one of claims 1-10 or a pharmaceutically acceptable salt thereof to prepare a medicament for treating a pathological condition associated with the FGF1R pathway in an animal (e.g. a mammal such as a human).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261675232P | 2012-07-24 | 2012-07-24 | |
US61/675,232 | 2012-07-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014018671A1 true WO2014018671A1 (en) | 2014-01-30 |
Family
ID=48916256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/051885 WO2014018671A1 (en) | 2012-07-24 | 2013-07-24 | Therapeutic compounds for the treatment of cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014018671A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015177668A1 (en) * | 2014-05-19 | 2015-11-26 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
US4608392A (en) | 1983-08-30 | 1986-08-26 | Societe Anonyme Dite: L'oreal | Method for producing a non greasy protective and emollient film on the skin |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
-
2013
- 2013-07-24 WO PCT/US2013/051885 patent/WO2014018671A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
US4608392A (en) | 1983-08-30 | 1986-08-26 | Societe Anonyme Dite: L'oreal | Method for producing a non greasy protective and emollient film on the skin |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
Non-Patent Citations (5)
Title |
---|
DONG, J-YAN ET AL: "Colomitides A and B: novel Ketals with an Unusual 2,-Dioxybicyclo[3.2.1]octance Ring System from the Aquatic Fungus YMF 1.01029", CHEMISTRY & BIODIVERSITY, vol. 6, no. 8, 2009, pages 1216 - 1223, XP002712225 * |
KAWAKAMI A ET AL., DEV DYN., vol. 231, no. 4, 2004, pages 693 - 699 |
LIJOY K. MATHEW ET AL., FASEB J., vol. 22, no. 8, August 2008 (2008-08-01), pages 3087 - 3096 |
TURNER, N. ET AL., CANCER RES., vol. 70, 2010, pages 2085 - 2094 |
WESTERFIELD, M.: "Zebrafish Book", 2000 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015177668A1 (en) * | 2014-05-19 | 2015-11-26 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
US9340553B2 (en) | 2014-05-19 | 2016-05-17 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR |
CN106459120A (en) * | 2014-05-19 | 2017-02-22 | 辉瑞大药厂 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
US9617293B2 (en) | 2014-05-19 | 2017-04-11 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR |
US10039778B2 (en) | 2014-05-19 | 2018-08-07 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR |
US10376531B2 (en) | 2014-05-19 | 2019-08-13 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR |
US10813942B2 (en) | 2014-05-19 | 2020-10-27 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10668062B2 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | |
KR20080083044A (en) | Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases | |
WO2008131320A1 (en) | Stilbene derivatives as new cancer therapeutic agents | |
WO2013109972A2 (en) | Therapeutic compounds | |
CN106279200B (en) | Abietane diterpenoid compound with hypolipidemic activity, and preparation method and application thereof | |
US10494341B2 (en) | Compound containing indoleacetic acid core structure and use thereof | |
WO2011153353A1 (en) | Tocopherol derivatives and methods of use | |
US10272055B2 (en) | Therapeutic compounds and methods | |
JP3577183B2 (en) | Arteriosclerosis prevention / treatment agent | |
JP5701387B2 (en) | Dicarboximide derivative of berbamine, its preparation method and use | |
WO2014018671A1 (en) | Therapeutic compounds for the treatment of cancer | |
WO2014009222A1 (en) | Combination therapy for the treatment of cancer and immunosuppression | |
CN115708410B (en) | Compound for targeted degradation of Btk and antitumor application thereof | |
EP2902028A1 (en) | Drug composition for treating tumors and application thereof | |
CN112292368A (en) | Synthesis of (+) -cannabinoids and therapeutic action thereof | |
EP3049400B1 (en) | New pi3k/akt/mtor inhibitors and pharmaceutical uses thereof | |
JP2009519301A (en) | Antitumor compounds | |
JP2016522223A (en) | Substance having tyrosine kinase inhibitory activity and preparation method and use thereof | |
CN108484635B (en) | 4H-thieno [2,3-b ] thiopyran-4-one compound and application thereof | |
JP7064094B2 (en) | Pharmaceutical use of cellular rattan diterpenes | |
CZ308865B6 (en) | Para-topolin mesylate salt, preparations containing it, and its use | |
CN114507139B (en) | Cyclopropane compound, preparation method thereof and application of cyclopropane compound in resisting influenza virus | |
RU2809986C2 (en) | New pheospheride derivatives with cytotoxic, anti-tumor activity and the ability to overcoming drug resistance | |
WO2012005581A1 (en) | Xanthanodien for the treatment of cancer | |
WO2016029669A1 (en) | Photo-hexyl ether compound, and pharmaceutical composition and usage thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13745300 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 03/07/2015) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13745300 Country of ref document: EP Kind code of ref document: A1 |